Long term effectiveness of low dose mithramycin for Paget's disease of bone

Area of Science:

• Bone Metabolism and Endocrinology
• Pharmacology and Therapeutics

Background:

• Paget's disease of bone is a chronic disorder characterized by abnormal bone remodeling.
• Current treatments aim to reduce bone turnover and alleviate symptoms.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of mithramycin in treating Paget's disease of bone.
• To assess pain relief and objective markers of disease activity post-treatment.

Main Methods:

• A cohort of 19 patients with Paget's disease of bone received mithramycin therapy.
• Treatment involved an average dose of 11.5 microgram/kg daily for 10 days.
• Patients were followed for 7 months to 5 years, assessing pain and objective disease markers.

Main Results:

• Thirteen out of 19 patients remained pain-free long-term.
• Objective measures, including serum alkaline phosphatase and bone scans, showed less favorable outcomes.
• No long-term toxicity was observed in the study group.

Conclusions:

• Mithramycin demonstrates significant long-term pain relief for Paget's disease of bone patients.
• While subjective pain improved, objective disease markers require further investigation.
• The drug appears to have a favorable long-term safety profile.